Compare JFrog Ltd. Ordinary Shares (FROG) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JFrog Ltd. Ordinary Shares vs Tango Therapeutics Inc. — how do they compare? JFrog Ltd. Ordinary Shares trades at $91 (market cap $12.24B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: JFrog Ltd. Ordinary Shares is far larger — about 3.3× Tango Therapeutics Inc.'s market cap, and JFrog Ltd. Ordinary Shares is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JFrog Ltd. Ordinary Shares for 5 Days and Tango Therapeutics Inc. for 0 Days on average.
| FROG | TNGX | |
|---|---|---|
Market Cap | $12.24B | $3.75B |
Volume | 1,786,951 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $104.03 | $32.90 |
52-Week Low | $34.75 | $7.50 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $11.43B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JFrog (FROG) trades at $99.28, up 0.26% on the day, showing strong technical momentum with a bullish moving average signal and trading near pivot point resistance at $99. The company has beaten earnings expectations for three consecutive quarters, with Q3 2026 results pending, while maintaining robust revenue growth projections from $532M in 2025 to $600M in 2026. Recent product announcements at swampUP 2026 focused on AI-era software supply chain security enhancements.
Wall Street maintains strong bullish sentiment with 87.5% buy ratings and a $110.25 consensus price target, representing 11% upside potential. However, negative profitability metrics and insider selling activity present near-term headwinds. The stock's elevated P/S ratio of 19.77 requires continued execution on growth targets to justify valuation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JFrog Ltd. Ordinary Shares
JFrog provides software supply chain tools that help developers manage, secure, and distribute software packages. Its platform is used across development and deployment workflows.
Read more on FROG →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
